1
|
Verma S, Crawford D, Khateb A, Feng Y, Sergienko E, Pathria G, Ma CT, Olson SH, Scott D, Murad R, Ruppin E, Jackson M, Ronai ZA. NRF2 mediates melanoma addiction to GCDH by modulating apoptotic signalling. Nat Cell Biol 2022; 24:1422-1432. [PMID: 36050469 PMCID: PMC9977532 DOI: 10.1038/s41556-022-00985-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Accepted: 07/26/2022] [Indexed: 11/09/2022]
Abstract
Tumour dependency on specific metabolic signals has been demonstrated and often guided numerous therapeutic approaches. We identify melanoma addiction to the mitochondrial protein glutaryl-CoA dehydrogenase (GCDH), which functions in lysine metabolism and controls protein glutarylation. GCDH knockdown induced cell death programmes in melanoma cells, an activity blocked by inhibition of the upstream lysine catabolism enzyme DHTKD1. The transcription factor NRF2 mediates GCDH-dependent melanoma cell death programmes. Mechanistically, GCDH knockdown induces NRF2 glutarylation, increasing its stability and DNA binding activity, with a concomitant transcriptional upregulation of ATF4, ATF3, DDIT3 and CHAC1, resulting in cell death. In vivo, inducible inactivation of GCDH effectively inhibited melanoma tumour growth. Correspondingly, reduced GCDH expression correlated with improved survival of patients with melanoma. These findings identify melanoma cell addiction to GCDH, limiting apoptotic signalling by controlling NRF2 glutarylation. Inhibiting the GCDH pathway could thus represent a therapeutic approach to treat melanoma.
Collapse
Affiliation(s)
- Sachin Verma
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - David Crawford
- Cancer Data Science Lab (CDSL), National Cancer Institute, National Institute of Health, Bethesda, MD 20892
| | - Ali Khateb
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Yongmei Feng
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Gaurav Pathria
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Chen-Ting Ma
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Steven H Olson
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - David Scott
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Rabi Murad
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Eytan Ruppin
- Cancer Data Science Lab (CDSL), National Cancer Institute, National Institute of Health, Bethesda, MD 20892
| | - Michael Jackson
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037
| | - Ze’ev A Ronai
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037,Correspondence: Ze’ev Ronai, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Rd, La Jolla, CA, 92037, USA.
| |
Collapse
|